138 Chapter 6 Trial Status Recruiting started on the 10th of September 2019. The current protocol is version 5.0 of 01 August 2022. Currently (12th of October 2023), we included 106 patients. Patient recruitment is estimated to be completed around December 2024. Conflicts of Interest The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: B.W.H. van der Arend, D.S. van Casteren, I.E. Verhagen, A. MaassenVanDenBrink and G.M. Terwindt report independent support from the Netherlands Organization for Health Research (849200007) and the Dutch Brain Foundation (HA2017.01.05). A. MaassenVanDenBrink reports consultancy or industry support from Novartis, Lillyand Teva, and Allergan/ Abbvie and independent support from the Dutch Research Council (Vici grant) and the Dutch Heart Foundation. G.M. Terwindt reports consultancy or industry support from Novartis, Lilly and Teva, Allergan/Abbvie, and Lundbeck and independent support from the European Community, Dutch Heart Foundation, IRRF and Dioraphte. Ethics approval and consent to participate The study is performed in accordance with the declaration of Helsinki Ethical Principles and Good Clinical Practices and was approved by the local and national ethics committees (NL67994.058.19). Funding This trial is supported by grants from the Netherlands Organization for Health Research (849200007) and the Dutch Brain Foundation (HA2017.01.05). Acknowledgements We thank our past, current and future participants of the WHAT! study.
RkJQdWJsaXNoZXIy MjY0ODMw